Xuefeng Qiu

Patient-derived organoids based on targeted biopsy of primary prostate cancer: development, identification, and drug screening

Jiajun Qian, Shan Peng, Jie Gao, Yao Fu et autres

cn (code pays fourni par la source)

The expression of prostate-specific membrane antigen in intraductal carcinoma of the prostate

Zheng Han, Binyu Wang, Shan Peng, Yao Fu et autres

cn (code pays fourni par la source)

WITHDRAWN: 2486P Quality of life analysis in patients with high-risk localized prostate cancer receiving neoadjuvant pamiparib plus abiraterone and ADT: A prospective study

Tingting Gong, Junlong Zhuang, S. Zhang, Xuefeng Qiu et autres

cn (code pays fourni par la source)

Locally advanced prostate cancer treated with neoadjuvant therapy combined with surgery: a multicenter retrospective cohort analysis

Shujun Liu, Shao‐Hao Chen, Jian-Hao Wu, Zhigang Wu et autres

cn (code pays fourni par la source)

IP05-30 THE PREDICTIVE VALUE OF GENETIC ALTERATIONS IN PSMA UPTAKE ALTERATION TO ENZALUTAMIDE: ANALYSIS IN A NEOADJUVANT HSPC COHORT

Jingyan Shi, Qinqin Xu, Yang Luo, Xuyu Zhang et autres

IP23-32 IMPACT OF NEOADJUVANT HORMONAL THERAPY ON URINARY CONTINENCE RECOVERY AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY: A MULTICENTER PROPENSITY SCORE-MATCHED ANALYSIS

Zhongqing Zhang, Hongqian Guo, Junlong Zhuang, Xuefeng Qiu et autres

Pathological and radiological features of false-positive lesions on [68Ga]Ga-PSMA-11 PET/CT in primary staging of prostate cancer: a radio-pathology matching analysis

Renjie Li, Yao Fu, Shan Peng, Fengjiao Yang et autres

cn (code pays fourni par la source)

A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in metastatic hormone sensitive prostate cancer patients with HRR gene mutation: Updated analysis of PROact.

Junlong Zhuang, Shun Zhang, Xuyu Zhang, Xuefeng Qiu et autres

cn (code pays fourni par la source)

Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial

Xuyu Zhang, Feng Zhou, Tong Lu, Shun Zhang et autres

cn (code pays fourni par la source)

A student trained convolutional neural network competing with a commercial AI software and experts in organ at risk segmentation

Sophia L. Bürkle, Dejan Kuhn, Tobias Fechter, Gianluca Radicioni et autres

de, cn, cy (code pays fourni par la source)

PROact: A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in patients with metastatic hormone sensitive prostate cancer with HRR gene mutation.

Junlong Zhuang, Shun Zhang, Xuyu Zhang, Xuefeng Qiu et autres

cn (code pays fourni par la source)

A PSMA PET/CT-based risk model for prediction of concordance between targeted biopsy and combined biopsy in detecting prostate cancer

Chaoli An, Xuefeng Qiu, Beibei Liu, Xiang Song et autres

cn (code pays fourni par la source)